Anúncio
Anúncio

ANIK

ANIK logo

Anika Therapeutics Inc

9.50
USD
Patrocinado
-0.05
-0.52%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

9.52

+0.02
+0.21%

Relatórios de Lucros ANIK

Rácio de surpresa positiva

ANIK separação 23 de 40 últimas estimativas.

57%

Próximo Relatório

Data do Próximo Relatório
10 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$29.45M
/
-$0.21
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+5.88%
/
+31.25%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-3.76%
/
-86.00%

Anika Therapeutics Inc earnings per share and revenue

On 05 de nov. de 2025, ANIK reported earnings of -0.16 USD per share (EPS) for Q3 25, beating the estimate of -0.27 USD, resulting in a 41.90% surprise. Revenue reached 27.82 milhão, compared to an expected 28.36 milhão, with a -1.90% difference. The market reacted with a +2.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analistas forecast an EPS of -0.21 USD, with revenue projected to reach 29.45 milhão USD, implying an aumentar of 31.25% EPS, and aumentar of 5.88% in Revenue from the last quarter.
FAQ
For Q3 2025, Anika Therapeutics Inc reported EPS of -$0.16, beating estimates by 41.9%, and revenue of $27.82M, -1.9% below expectations.
The stock price moved up 2.28%, changed from $9.63 before the earnings release to $9.85 the day after.
The next earning report is scheduled for 10 de mar. de 2026.
Based on 4 analistas, Anika Therapeutics Inc is expected to report EPS of -$0.21 and revenue of $29.45M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio